Peginterferon-alpha 2a for the Treatment of Hepatitis B Infection

Cooksley, W. Graham E. (2005) Peginterferon-alpha 2a for the Treatment of Hepatitis B Infection. Expert Opinion on Pharmacotherapy, 6 8: 1373-1380. doi:10.1517/14656566.6.8.1373

Author Cooksley, W. Graham E.
Title Peginterferon-alpha 2a for the Treatment of Hepatitis B Infection
Formatted title
Peginterferon-α2a for the treatment of Hepatitis B infection 
Journal name Expert Opinion on Pharmacotherapy   Check publisher's open access policy
ISSN 1465-6566
Publication date 2005-07
Sub-type Article (original research)
DOI 10.1517/14656566.6.8.1373
Volume 6
Issue 8
Start page 1373
End page 1380
Total pages 8
Place of publication London, United Kingdom
Publisher Informa Healthcare
Language eng
Subject 1103 Clinical Sciences
Formatted abstract
Chronic hepatitis B is one of the world’s most common serious diseases with > 300 million patients worldwide. Currently recommended treatments include conventional interferon (IFN), lamivudine and adefovir. Recently, peginterferon-α2a (PEG-IFN-α2a, Pegasys®; Hoffmann-La Roche & Co.) has been approved for use in patients with chronic hepatitis B in the US, the EU, Switzerland, Turkey and in several countries in the Asia-Pacific region. Several trials have been carried out using PEG-IFN-α2a (40 kDa) compared with conventional IFN, lamivudine monotherapy and a combination of PEG-IFN-α2a and lamivudine in patients with hepatitis Be antigen- (HBeAg) positive chronic hepatitis B, and patients with HBeAg-negative chronic hepatitis B. PEG-IFN-α2a was shown to be superior to conventional IFN in HBeAg-positive disease and to lamivudine in both HBeAg-positive and HBeAg-negative chronic hepatitis B. Although there was greater suppression of virus while on therapy, the combination of lamivudine and PEG-IFN-α2a did not enhance sustained response at the end of the 24-week follow-up period, compared with PEG-IFN monotherapy. In addition, ~ 3% of patients underwent hepatitis B surface antigen (HBsAg) seroconversion – the ultimate marker of therapeutic response, which is rarely seen following treatment with antiviral agents. The side effect profile was reasonable. PEG-IFN-α2a could become the treatment of choice in many patients with both HBeAg-positive and HBeAgnegative disease and, in those who fail to respond, consideration could then be given to the use of antiviral agents
Keyword adefovir
chronic hepatitis B
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
ERA 2012 Admin Only
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 5 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 8 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 12 Mar 2009, 16:15:44 EST by Alexandra Cooney on behalf of Medicine - Royal Brisbane and Women's Hospital